• OUR COVID-19 RESPONSE – Updated May 7, 2020

  • IMMUNIVATION: Discover our approach to immune activation

iStock_37438014_XXXLARGE-outlined_LM.png pink_scrubs.png hp-people-3.png man-in-sweater_90824869_v1MAG.png Dr-Glasses.png iStock_86712797_XXXLARGE-outline_LM.png blue_shirt_masthead_man_v1_MAG.png NKT-hp-people-Michelle_v1_LM.png iStock_68713947_XXLARGE-outiline_LM.png NKT-hp-people-Phi_v1_LM.png NKT-hp-people-Mekhala_v1_LM.png hp-people-3.png iStock_87627749_XXXLARGE-outline_LM.png

Events

NOV 11

Conference Call for Analysts at SITC
Virtual
4:15 PM EST

Listen to Webcast

NOV 05

Q3 Earnings
Virtual
17:00 Eastern Time (2:00 PM PT)

Conference ID: 5192707
Listen to Webcast

NOV 04

Conference Call for Analysts at ACR
Virtual
4:15 PM EST

Listen to Webcast

Explore the IL-2 Pathway

Learn about the role of the interleukin-2 (IL-2) pathway in activating the immune system.

Watch

Immunivation IL-2 video

Latest News

OUR PIPELINE

We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.

Bempegaldesleukin

IMMUNO-ONCOLOGY

PHASE 3

  • 9

    9 million patients benefit from our medicines

    9
    9
    9

  • 12

    12 approved products around the world

    12
    12
    12

  • 10

    10 new medicines in development pipeline

    10
    10
    10


Cutting-edge facilities




Dynamic teams




Impactful work


OUR Culture

We are supported by a dynamic team, rich in scientific, business and medical expertise, across three locations.

Read more